The quest for fragile X biomarkers
1Department of Neurology, University of Wisconsin-Madison, Madison, WI, USA. westmark@wisc.edu.
Background:
Fragile X is the most common form of inherited intellectual disability and the leading known genetic cause of autism. There is currently no cure or approved medication for fragile X although various drugs target specific disease symptoms and a large number of therapeutics are in various stages of clinical development. Multiple recent clinical trials have failed on their primary endpoints indicating that there is a compelling need for validated biomarkers and outcome measures in fragile X.
Findings:
There are currently no validated blood-based biomarkers to assess disease severity or to monitor drug efficacy in fragile X syndrome. Herein, we review candidate blood protein biomarkers including extracellular-regulated kinase, phosphoinositide 3-kinase, matrix metalloproteinase 9, amyloid-beta and amyloid-beta protein precursor.
Conclusions:
Bench-to-bedside plans for fragile X syndrome are severely limited by the lack of validated outcome measures. The reviewed candidate biomarkers are at early stages of validation and deserve further investigation.
Insights
Fragile X syndrome lacks validated blood biomarkers for assessing severity or drug effectiveness. This review examines candidate protein biomarkers, highlighting the need for further research to advance treatments.
Area of Science:
- Neurogenetics
- Biomarker Discovery
- Pharmacology
Background:
- Fragile X syndrome is the most common inherited intellectual disability and a leading genetic cause of autism.
- Current treatments for Fragile X syndrome focus on symptom management, with no cure available.
- Recent clinical trials highlight the urgent need for validated biomarkers and outcome measures in Fragile X research.
Purpose of the Study:
- To review candidate blood protein biomarkers for Fragile X syndrome.
- To identify potential markers for assessing disease severity and monitoring therapeutic efficacy.
Main Methods:
- Literature review of candidate blood protein biomarkers.
- Analysis of biomarkers including extracellular-regulated kinase, phosphoinositide 3-kinase, matrix metalloproteinase 9, amyloid-beta, and amyloid-beta protein precursor.
Main Results:
- No validated blood-based biomarkers currently exist for Fragile X syndrome.
- Several candidate protein biomarkers have been identified for further investigation.
Conclusions:
- The development of validated outcome measures is critical for advancing Fragile X syndrome research and treatment.
- The reviewed candidate biomarkers show promise but require extensive validation before clinical application.
More Related Videos
11:10Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
10:59Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein
Published on: June 6, 2025
